Becton, Dickinson and Company (NYSE:BDX) to Issue $1.05 Quarterly Dividend

Becton, Dickinson and Company (NYSE:BDX) announced a quarterly dividend on Tuesday, January 27th. Shareholders of record on Tuesday, March 10th will be paid a dividend of 1.05 per share by the medical instruments supplier on Tuesday, March 31st. This represents a c) dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Tuesday, March 10th.

Becton, Dickinson and Company has increased its dividend by an average of 0.1%annually over the last three years and has raised its dividend every year for the last 53 years. Becton, Dickinson and Company has a dividend payout ratio of 28.5% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Becton, Dickinson and Company to earn $15.64 per share next year, which means the company should continue to be able to cover its $4.20 annual dividend with an expected future payout ratio of 26.9%.

Becton, Dickinson and Company Stock Performance

BDX stock traded down $0.71 during midday trading on Wednesday, hitting $202.69. 585,915 shares of the company traded hands, compared to its average volume of 1,706,391. Becton, Dickinson and Company has a twelve month low of $162.29 and a twelve month high of $251.99. The stock has a market capitalization of $57.75 billion, a price-to-earnings ratio of 34.73, a price-to-earnings-growth ratio of 2.25 and a beta of 0.23. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69. The business has a 50 day simple moving average of $197.87 and a 200-day simple moving average of $190.90.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The business had revenue of $5.89 billion during the quarter, compared to analysts’ expectations of $5.91 billion. During the same period in the previous year, the company earned $3.81 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 8.3% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company announced that its board has initiated a share buyback plan on Tuesday, January 27th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.